Navigation Links
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
Date:4/24/2008

PALO ALTO, Calif., April 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending approval of ranolazine in the European Union (EU) for the treatment of chronic angina.

Following this positive recommendation from the CHMP, CV Therapeutics expects the European Commission to issue full marketing authorization for ranolazine by the end of June. The brand name for ranolazine in the product labeling is Latixa(TM).

The approved indication states that ranolazine "is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists)."

The labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness. The doses of the product in the EU will be 375 mg, 500 mg and 750 mg twice daily.

"This positive opinion from the CHMP brings ranolazine significantly closer to physicians and patients in Europe for the treatment of chronic angina," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "The strong first-in-class product labeling should position ranolazine very favorably with potential partners and allow for broad patient acceptance and premium pricing in the E
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)...  ResMed (NYSE: RMD ) today ... program, a comprehensive suite of software and service ... health care providers. ResMed Data ... information. It integrates valuable sleep and respiratory treatment ... platforms with customers, in-house or third-party electronic health ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... the puzzle in helping Canadians gain access to treatments for rare diseases ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Oct. 26 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... teleconference with management to provide a general business overview, as ... Wednesday, November 3, 2010, at 5:00 p.m. Eastern Time (2:00 ... September 30, 2010 will be released earlier that day. ...
Cached Medicine Technology:Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 2Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 3Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 4Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 5Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 6Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 7Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 8Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 9Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast 2
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... - make rounds to assist those ... ... 700,dialysis patients requiring vital services benefited from the emergency,response efforts enacted by ... kidney care services, during the recent wildfires,affecting areas of Southern California. The ...
... Local residents show America how they ,Think About Their Drink, ST. LOUIS, ... prize winner of the Think About ... The Maples family entered the photo contest by submitting a ... As part of a ...
... they ,Think About Their Drink, NEW HAVEN, Conn., Oct. 29 , WHO: ... among the 25 winning families ... Drink Family Challenge from hundreds of entrants nationwide., WHAT: The ... submitting a creative snapshot of their gangs choosing ...
... 29, 2007 -- Another disease can be added ... Researchers have found that smoking increases the risk ... further, and the risk decreases only slowly after ... and Women,s Hospital, the Harvard School of Public ...
... physicians improve ... administrative burden., ANNAPOLIS, Md., Oct. 29 ... today announced the,introduction of CBayPraxis. (Logo: ... electronic patient folder, a simple,intuitive, and web enabled ...
... is marked by the breakdown of articular cartilage, which ... of most limb bones. It can afflict any ... as well as the weight-bearing knees and hips. ... affected joint. This inflammation has been attributed to ...
Cached Medicine News:Health News:DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 3Health News:MilkPEP: New Haven Area Families Win Nationwide got milk? Contest 2Health News:MilkPEP: New Haven Area Families Win Nationwide got milk? Contest 3Health News:New study shows smoking increases risk of psoriasis 2Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 2Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 3Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 4Health News:New insights into inflammation in osteoarthritis 2Health News:New insights into inflammation in osteoarthritis 3
... kg, Interior Dimensions (WxDxH): 31.1 x 13.6 ... 44.6 x 22.4 x 20.5 cm, Capacity: ... - 300 x 35 mm bottles, 4 ... 1 - 240 x 80 mm bottle, ...
... The Minifold I system consists of four ... vacuum plenum, and metal clamping plate (see diagram). ... configurations for producing spots, dots, or slots (see ... be purchased as an accessory plate in conjunction ...
... Bio-Dot SF (slot format) microfiltration units provide ... nucleic acid in solution onto nitrocellulose or ... accommodated by using interchangeable templates to form ... format Bio-Dot SF apparatus. Each is available ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Medicine Products: